Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21105566 | 0.86 | DRD2 (0.48) | DRD2MEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL2010604 | 0.82 | TSHR (0.53) | MEN1KMT2AALDH1A1TSHRSIGMAR1 | |
| SCHEMBL2010392 | 0.80 | ALDH1A1 (0.67) | MEN1KMT2AALDH1A1TSHRSIGMAR1 | |
| SCHEMBL24817860 | 0.79 | MEN1 (0.46) | DRD2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL22699069 | 0.78 | DRD2 (0.54) | DRD2MEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL18947871 | 0.78 | DRD2 (0.54) | DRD2MEN1KMT2ASIGMAR1TDP1 | |
| SCHEMBL24619896 | 0.78 | DRD2 (0.54) | DRD2MEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL829106 | 0.78 | DRD2 (0.54) | DRD2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8254760 | 0.78 | DRD2 (0.64) | DRD2MEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL6700 | 0.77 | DRD2 (0.53) | DRD2MEN1KMT2ASIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | DRD2 162/4885MEN1 474/4885KMT2A 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.